Premium
Synthesis and anticancer activity of Pt(0)‐olefin complexes bearing 1,3,5‐triaza‐7‐phosphaadamantane and N ‐heterocyclic carbene ligands
Author(s) -
Scattolin Thomas,
Valente Giorgia,
Luzietti Lara,
Piva Michele,
Demitri Nicola,
Lampronti Ilaria,
Gambari Roberto,
Visentin Fabiano
Publication year - 2021
Publication title -
applied organometallic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 71
eISSN - 1099-0739
pISSN - 0268-2605
DOI - 10.1002/aoc.6438
Subject(s) - chemistry , cisplatin , hacat , k562 cells , chronic myelogenous leukemia , stereochemistry , carbene , in vitro , cell culture , apoptosis , ligand (biochemistry) , mechanism of action , leukemia , platinum , cancer cell , biochemistry , cancer , receptor , chemotherapy , immunology , medicine , genetics , surgery , biology , catalysis
A series of Pt(0)‐ η 2 ‐olefin complexes bearing 1,3,5‐triaza‐7‐phosphaadamantane (PTA) or N ‐heterocyclic carbenes are prepared following different synthetic strategies depending on the nature of coordinated alkene and spectator ligands. These new platinum(0) derivatives have been tested in vitro as anticancer agents toward three different tumor (human ovarian cancer A2780 and A2780 cis and K562 myelogenous leukemia) and one non‐tumor (Hacat keratinocytes) cell lines, proving to be in several cases highly and selectively cytotoxic against ovarian cancer cells. Furthermore, this antiproliferative effect is associated with the activation of an apoptosis process. In particular, complexes equipped with PTA as spectator ligand give comparable IC 50 values on A2780 (cisplatin sensitive) and A2780 cis (cisplatin resistant) cell lines, indirectly proving that these new Pt(0) substrates act with a mechanism of action conceivably different from cisplatin. This hypothesis is also confirmed by the fact that our compounds, in contrast to cisplatin, are not able to promote erythroid‐differentiation activity on the K562 myelogenous leukemia cell line.